Ketamine Self-Medication in a Patient with Autism Spectrum Disorder and Comorbid Therapy-Resistant Depression

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Autism spectrum disorder (ASD) and treatment-resistant mood disorders with suicidality present significant clinical challenges.
• Current psychopharmacological treatments, including risperidone and valproic acid, were ineffective for this patient.
• The patient exhibited severe functional impairment, including limited social functioning and chronic suicidality.

Observation:

• The patient engaged in self-medication with ketamine after multiple failed treatments.
• Following ketamine use, the patient reported complete remission of depression and suicidality.
• Significant improvements in core autism spectrum disorder symptoms were also noted by the patient.

Findings:

• This case suggests ketamine may be effective in treating comorbid depression and suicidality in adults with ASD.
• Preliminary evidence indicates potential benefits of ketamine for certain autism spectrum disorder symptoms.
• The patient's response highlights a potential novel therapeutic avenue for complex psychiatric conditions.

Implications:

• Ketamine shows promise as a treatment for severe mood disorders and suicidality, even in complex cases like comorbid ASD.
• Further research is warranted to explore ketamine's efficacy and safety profile for ASD symptoms.
• Increased awareness of ketamine's effects necessitates caution regarding unsupervised self-medication due to potential risks.